Annovis Bio announces publication on buntanetap

Annovis Bio announced the publication of new data from an earlier study supporting buntanetap as a translational inhibitor of amyloid precursor protein in patients with early Alzheimer’s Disease. In this randomized, double-blind, placebo-controlled study, participants received oral buntanetap up to a 25-day period. At the end of the study, patients were catharized in the lumbar spine for 36 hours to accommodate the total time it takes for APP to be synthesized, processed into Abeta, and degraded. Notably, the analysis of adverse events demonstrated no dose-dependent effect of buntanetap compared to placebo, affirming the drug’s safety and tolerability. Furthermore, multiparameter modeling of APP kinetics provided additional evidence for dose-dependent lowering of APP production by buntanetap. A model that included the pre-drug lumbar CSF concentration as a covariate showed statistical significance between the placebo and 120, 180 mg per day buntanetap groups, suggesting a drug effect on lowering APP production. In general, buntanetap lowered the rate of translation, the maximum concentration, lengthened the Tmax, and decreased the area under the curve.